Non-invasive prostate cancer test may reduce biopsies

The French firm bioMérieux and ProteoSys, based in Mainz, Germany, have signed a license and development agreement for Annexin 3 to be used to develop a urine-based, confirmatory diagnostic test for prostate cancer.

After a research phase, the new test should be developed on the VIDAS platform.
Annexin 3, also known as ANXA 3, was discovered by ProteoSys, which specialises in cell biology and proteomics. Studies have shown that ANXA 3 quantification in urine is a novel, non-invasive test with high specificity for prostate cancer. Today, when the levels of prostate specific antigen (PSA) are in the uninformative ‘grey zone’, a biopsy is used to provide definitive diagnosis. The ANXA 3 test would be used to provide better identification of patients with a high probability of prostate cancer, thereby reducing the number of unnecessary biopsies.
After the first research phase at bioMérieux, a diagnostic test for the VIDAS platform will be developed. While the confirmatory diagnostic application on VIDAS will be the initial focus, bioMérieux is also considering the development of treatment decision and prognostic applications for ANXA 3.

28.10.2008

More on the subject:
Read all latest stories

Related articles

Photo

Article • Improving quality and efficiency

Preparing for AI in clinical laboratories

Some year in this decade, AI tools will become ubiquitous within clinical laboratories. AI has the potential to increase the accuracy of laboratory testing and improve the quality and efficiency of…

Photo

News • Personalised oncology

New platform to significantly reduce cancer drug testing and screening time

In a breakthrough for personalised oncology, scientists have developed and demonstrated a novel platform that can significantly reduce the time needed to determine the efficacy of anti-cancer drugs.

Photo

News • Cortisol sampling from blood

Paving the way for better diagnosis and treatment of endocrine diseases

A team of researchers has discovered a new method of measuring levels of cortisol directly from a blood sample - a significant step forward in diagnosis and treatment of a wide range of diseases.

Related products

Subscribe to Newsletter